$
0.000
0.000(0.000%)
  • Overview
  • Forecast
  • Valuation
  • Earnings

Earning Analysis

Welcome to our in-depth analysis of AstraZeneca PLC(AZN) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of AstraZeneca PLC earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.

Earnings Forecast

Revenue
EPS
Currency: USD
Actual
Estimate

Surprise Analysis

Name
EPS
Revenue
Price Reaction
Fiscal QuarterEarning DateTimeEstimateActualSurprise%EstimateActualSurprise%1D5D
FY2025Q12025-04-29Pre-Market1.101.24+12.7313.74B13.59B-1.11+2.55+3.59
FY2024Q42025-02-06Pre-Market1.071.05-1.8714.18B14.89B+5.01+2.01+4.93
FY2024Q22024-07-25-0.960.99+3.1312.53B12.94B+3.28-1.49-0.70
FY2024Q12024-04-25-0.951.03+8.4211.81B12.68B+7.34+5.38+7.32
FY2023Q42024-02-08-0.740.73-1.3512.01B12.02B+0.14-4.55-7.35
FY2023Q32023-11-09-0.800.87+8.7511.53B11.49B-0.32+0.88-0.63
FY2023Q22023-07-28-0.971.08+11.3411.02B11.42B+3.62+4.68+2.25
-2023-04-27-0.860.96+11.63---+0.18+1.28
-2023-02-09-0.680.69+1.47---+4.75+8.28
-2022-11-10-0.770.84+9.09---+6.62+4.50

AZN Earnings Analysis

Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, AstraZeneca PLC reported performance for FY2025Q1, announced on 2025-04-29. The company achieved an EPS of 1.24, compared to analyst estimates of 1.10 by 12.73% . Revenue for the quarter reached 13.59B compared to expectations of 13.74B by -1.11% .
The stock price reacted with a 2.55% one-day change and a 3.59% five-day change following the earnings release. These movements reflect market reaction in AstraZeneca PLC growth trajectory and strategic initiatives.

AZN Earnings Forecast

Looking ahead, AstraZeneca PLC(AZN) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q2 project quarter revenue of 14.08B and an EPS of 1.14.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 0.91%, while EPS estimates have been Revise Upward by 101.79%. For the upcoming Q2 2025, revenue estimates have been adjusted Revise Upward by 0.71% . These revisions correlate with a -4.30% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in AstraZeneca PLC long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.

Estimate Revision

The chart shows the correlation between AZN's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.91%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+101.79%
In Past 3 Month
Revenue Estimates for Q2 2025
Revise Upward
up Image
+0.71%
In Past 3 Month
Stock Price
Go Down
down Image
-4.30%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
--
Revenue Estimate-Annual FY 2025:57.81B
--
EPS Estimate-Annual FY 2025:9.02
Stock Price72.83

AZN Revenue and EPS Performance: A Historical Perspective

AstraZeneca PLC revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q1 (2025-04-29,Pre-Market):
EPS: 1.24 (Actual) vs.1.10 (Estimate) (12.73%)
Revenue: 13.59B (Actual) vs. 13.74B (Estimate) (-1.11%)
Price Reaction: 2.55%(1-Day), 3.59%(5-Day)
FY2024Q4 (2025-02-06,Pre-Market):
EPS: 1.05 (Actual) vs.1.07 (Estimate) (-1.87%)
Revenue: 14.89B (Actual) vs. 14.18B (Estimate) (5.01%)
Price Reaction: 2.01%(1-Day), 4.93%(5-Day)
FY2024Q2 (2024-07-25,):
EPS: 0.99 (Actual) vs.0.96 (Estimate) (3.13%)
Revenue: 12.94B (Actual) vs. 12.53B (Estimate) (3.28%)
Price Reaction: -1.49%(1-Day), -0.70%(5-Day)
Earnings Reaction
The chart below shows how AZN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, AZN sees a -3.19% change in stock price 10 days leading up to the earnings, and a +1.27% change 10 days following the report. On the earnings day itself, the stock moves by +2.10%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in MAR/2025, the stock changed 0.11% on the day following the earnings release and then changed by -5.56% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.

Transcript Summary

AstraZeneca PLC (AZN) Q1 2025 Earnings Call Summary
Neutral
2025-04-29
The earnings call summary presents a mixed outlook. Financial performance shows growth in revenue and cash inflows, but also increased expenses and net debt. Product development is promising with pipeline advancements, yet financial investigations in China pose a risk. Market strategy is positive with emerging market growth, but U.S. pricing uncertainties remain. Shareholder returns are stable with dividends, but no significant changes. Q&A insights reveal confidence in product potential, but management's unclear responses on strategic timelines and pricing impact add uncertainty. Overall, the sentiment is neutral due to balanced positives and negatives.
AstraZeneca PLC (AZN) Q4 2024 Earnings Call Summary
Neutral
2025-02-07
The earnings call reveals mixed signals: strong emerging market growth and a share buyback program are positives, but issues like regulatory investigations in China, missed earnings expectations, and unclear management responses raise concerns. The upgraded guidance and strategic focus in China and emerging markets provide optimism. However, the potential fines and competitive pressures balance this out, leading to a neutral sentiment. The lack of market cap data prevents assessing potential volatility, but overall, the stock is likely to remain stable in the short term.
AstraZeneca PLC (AZN) Q3 2024 Earnings Call Summary
Neutral
2024-11-12
The earnings call reveals strong revenue growth, but concerns about regulatory issues in China, competitive pressures, increased debt, and supply chain challenges offset the positives. The Q&A section highlights management's uncertainty about the impact of these issues, particularly in China, and vague responses to analyst queries. Despite upgraded guidance and record revenue, financial challenges and uncertainties lead to a neutral sentiment rating, with no clear indication of a strong positive or negative short-term stock movement.
AstraZeneca PLC (AZN) Q2 2024 Earnings Call Summary
Neutral
2024-07-25
The earnings call summary presents a mix of positive and negative signals. Strong financial performance and promising pipeline developments are countered by increased debt and supply chain challenges. The Q&A session highlights uncertainties in revenue growth and competitive pressures, particularly in China. Despite a dividend increase and optimistic guidance, the adverse foreign exchange impact and rising expenses temper enthusiasm. Given these mixed signals, a neutral stock price reaction is expected over the next two weeks.

FAQ

arrow icon

What were the key highlights of AZN’s latest earnings report for FY2025Q1?

AZN reported its FY2025Q1 earnings on 2025-04-29, showcasing a revenue of 13.59B against an estimate of 13.74B, resulting in a -1.11% surprise. The EPS was 1.24, surpassing the expected 1.1 by 12.73% . The stock experienced a 2.55% price change on the earnings day and a 3.59% change over the next five days, reflecting market reactions to the results.
arrow icon

How did AZN’s stock price react after the FY2025Q1 earnings release?

arrow icon

What are the revenue and EPS estimates for AZN for 2025/Q2?

arrow icon

How does AZN’s stock price correlate with earnings forecast revisions?

arrow icon

What should investors expect from AZN’s next earnings report?

arrow icon

What is the sentiment in AstraZeneca PLC (AZN) Q1 2025 Earnings Call Summary?